Jerry Durso, Intercept Pharmaceuticals CEO

In­ter­cept sells ex-US rights to PBC drug as it gears up for a sec­ond-chance shot at NASH

In­ter­cept Phar­ma­ceu­ti­cals, the biotech that brought NASH to the fore­front of drug de­vel­op­ment R&D, has sold off the ex-US rights to its au­toim­mune dis­ease drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.